1. Home
  2. PRAX vs LEGN Comparison

PRAX vs LEGN Comparison

Compare PRAX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$282.31

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo Legend Biotech Corporation

LEGN

Legend Biotech Corporation

HOLD

Current Price

$27.93

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
LEGN
Founded
2015
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
5.9B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
PRAX
LEGN
Price
$282.31
$27.93
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
12
Target Price
$572.13
$61.33
AVG Volume (30 Days)
475.2K
3.1M
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$42.68
Revenue Next Year
$7,758.26
$30.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$37.25
$16.24
52 Week High
$366.52
$45.30

Technical Indicators

Market Signals
Indicator
PRAX
LEGN
Relative Strength Index (RSI) 47.14 43.10
Support Level $238.77 $23.10
Resistance Level $342.62 $28.70
Average True Range (ATR) 21.47 2.86
MACD 0.62 -0.55
Stochastic Oscillator 39.34 24.59

Price Performance

Historical Comparison
PRAX
LEGN

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Share on Social Networks: